(a) Research for the development of well-characterized and more-defined medical marijuana products for treatment of target indications, including demonstrations of safety and efficacy for treatment of medical conditions that often fail to respond to conventional treatment, may be conducted in Delaware.
(b) Research performed under the authority of this chapter shall be conducted as follows:
(1) In a facility which meets FDA-accepted security and operational standards.
(2) Using practices and standards that ensure uniformity, consistency, reliability, reproducibility, quality, and integrity of data, including good laboratory standards (GLP) when required.
(3) On plants grown from well-characterized and well-defined seed stock.